News

AbbVie Inc. (NYSE: ABBV) delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an increase in its forward guidance. The results clear the way for ABBV stock

Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock, while a blockbuster approval can generate spectacular returns. For many

If UnitedHealth Group’s (NYSE: UNH) stock price implosion was driven by margin, earnings, and capital return concerns, the Q3 results put them to rest.

While the business reflects margin

UnitedHealth Group (NYSE: UNH) has staged a formidable comeback, with its stock up over 29% in the last 90 days as investors embraced management's aggressive turnaround strategy. This powerful

For many investors, getting involved with pharmaceutical stocks involves finding inexpensive stocks, often penny stocks, in hopes of investing in a breakthrough treatment for cancer, Alzheimer’s

There are two types of Halloween people: those who like jump scares and those who don’t. But even if you’re a fan of haunted hayrides and movies like The Conjuring, you probably don’t want to ever

Abbott Laboratories' (NYSE: ABT) October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a

After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of